David Saxon, an analyst from Needham, reiterated the Buy rating on RxSight. The associated price target was raised to $12.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Saxon has given his Buy rating due to a combination of factors including RxSight’s impressive third-quarter revenue performance, which exceeded market expectations. The company’s management has also raised the midpoint of its financial guidance, indicating confidence in future growth.
Additionally, RxSight is adopting a more strategic approach to its LDD placements, focusing on increasing LAL volumes through various engagement initiatives. The company is also targeting consistent quarterly growth in 2026, and its gross margin is expected to remain robust, staying in the high-70% range. These positive indicators collectively support the Buy rating.